Calgary Startup Syantra to Launch Innovative Breast Cancer Blood Test
Syantra, a Calgary-based startup, is set to launch Onco-ID, a groundbreaking breast cancer blood test, this summer. Unlike traditional methods, Onco-ID identifies immune signals rather than searching for cancer cells directly, potentially offering earlier and more accurate detection than mammograms.
Syantra’s Innovative Approach
Founded in 2016, Syantra emerged from the University of Calgary with a focus on biomarker and drug discovery. The company, led by co-founders Dr. Kristina Rinker and Bob Shepherd, pivoted from cardiovascular disease to breast cancer, developing a unique biomarker combination. Onco-ID uses machine learning to detect patterns of gene expression indicating the body’s immune response to cancer, rather than relying on circulating tumour DNA.
Context and Competition
Breast cancer detection has traditionally relied on mammograms, but these have limitations, especially for women with dense breast tissue, which can obscure tumours. Syantra’s test addresses this issue by focusing on immune responses, potentially offering a more effective screening method. While other tests, like Galleri, can detect multiple cancer types, Syantra is concentrating on breast cancer, aiming for high accuracy in specific areas.
Market Implications
The upcoming launch of Onco-ID follows years of development and clinical trials in Canada, the US, and the UK. Syantra’s CEO, Rob Lozuk, highlights the importance of statistical validation, with data expected to be released in May. The test is priced similarly to other cancer screening tests, at around $500 per test, and the company is working towards insurance coverage and inclusion in clinical guidelines.
Looking Ahead
Syantra’s focus on breast cancer detection could mark a significant advancement in early diagnosis. With plans to expand to other cancer types, the company is poised to make a substantial impact in the field of cancer diagnostics. The launch of Onco-ID this summer will be a critical step in this journey, offering a new tool in the fight against breast cancer. For more information, visit Syantra’s website.
